suramin has been researched along with Lung Neoplasms in 33 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suramin inhibits the growth of non-small cell lung cancer (NSCLC) and breast cancer in vitro by blocking the action of most known growth factors." | 9.08 | Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. ( Bergh, J; Jakobsen, E; Lindebjerg-Clasen, B; Mirza, MR; Pfeiffer, P; Rose, C, 1997) |
| " This study was to explore the inhibitory effect of angiogenesis inhibitor Suramin in combination with cisplatin (DDP) on the growth and lung metastasis of lung adenocarcinoma LA795 cell xenografts in mice." | 7.73 | [Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice]. ( He, JB; Ou, LW; Wang, XH; Zhang, P, 2006) |
| "To better understand the molecular basis for the cytotoxic effects of suramin, we have developed suramin-resistant DC-3F/SU 1000 cells by continuous exposure of fibrosarcoma cells to increasing concentrations of suramin." | 7.69 | Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells. ( Benchokroun, Y; Larsen, AK; Lelièvre, S, 1995) |
| "Suramin-resistant DC-3F/SU 1,000 Chinese hamster fibrosarcoma cells were obtained by continuous exposure of parental DC-3F cells to increasing concentrations of suramin (1 mg/ml final concentration)." | 7.69 | Development and characterization of suramin-resistant Chinese hamster fibrosarcoma cells: drug-dependent formation of multicellular spheroids and a greatly enhanced metastatic potential. ( Larsen, AK; Lelièvre, S, 1994) |
| "Emodin is an anthraquinone derivative originally isolated from Chinese rhubarb, possesses anticancer properties." | 5.46 | Emodin Inhibits ATP-Induced Proliferation and Migration by Suppressing P2Y Receptors in Human Lung Adenocarcinoma Cells. ( Guan, R; Li, L; Shen, L; Song, N; Wang, X; Zhu, D, 2017) |
| "Suramin treatment before cisplatin administration reduced cisplatin-induced decreases in kidney function and injury." | 5.43 | Suramin protects from cisplatin-induced acute kidney injury. ( Arteel, GE; Beverly, LJ; Casson, L; Doll, MA; Dupre, TV; Jenson, AB; Kiefer, A; Megyesi, J; Saforo, D; Saurabh, K; Scherzer, MT; Schnellmann, RG; Shah, PP; Sharp, CN; Siow, D; Siskind, LJ, 2016) |
| "Suramin is a polyanionic agent which has been found to be an effective antineoplastic agent against various human tumors including adrenal, renal and prostatic cancer, and osteosarcoma." | 5.29 | Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer. ( Boyce, BF; Dunstan, C; Mundy, GR; Rhine, C; Williams, P; Yoneda, T, 1995) |
| "Treatment with suramin (Germanin) was begun in August 1987." | 5.28 | [Treatment of metastatic adrenal carcinoma with suramin]. ( Allolio, B; Arlt, W; Jaursch-Hancke, C; Metzler, U; Reincke, M; Winkelmann, W, 1989) |
| "Suramin inhibits the growth of non-small cell lung cancer (NSCLC) and breast cancer in vitro by blocking the action of most known growth factors." | 5.08 | Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. ( Bergh, J; Jakobsen, E; Lindebjerg-Clasen, B; Mirza, MR; Pfeiffer, P; Rose, C, 1997) |
| "Recent study found that suramin could inhibit the growth of malignant tumors, but its in vivo effect on lung adenocarcinoma has seldom been reported." | 3.74 | [Inhibitory effects of suramin on growth of transplanted lung adencarcinoma in mice and its mechanisms]. ( He, JB; Xiang, Z; Xie, MF; Yang, K; Yi, GZ; Zhang, P, 2008) |
| " This study was to explore the inhibitory effect of angiogenesis inhibitor Suramin in combination with cisplatin (DDP) on the growth and lung metastasis of lung adenocarcinoma LA795 cell xenografts in mice." | 3.73 | [Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice]. ( He, JB; Ou, LW; Wang, XH; Zhang, P, 2006) |
| "To better understand the molecular basis for the cytotoxic effects of suramin, we have developed suramin-resistant DC-3F/SU 1000 cells by continuous exposure of fibrosarcoma cells to increasing concentrations of suramin." | 3.69 | Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells. ( Benchokroun, Y; Larsen, AK; Lelièvre, S, 1995) |
| "Suramin-resistant DC-3F/SU 1,000 Chinese hamster fibrosarcoma cells were obtained by continuous exposure of parental DC-3F cells to increasing concentrations of suramin (1 mg/ml final concentration)." | 3.69 | Development and characterization of suramin-resistant Chinese hamster fibrosarcoma cells: drug-dependent formation of multicellular spheroids and a greatly enhanced metastatic potential. ( Larsen, AK; Lelièvre, S, 1994) |
| " Target plasma concentrations were correctly predicted by our previously described dosing nomogram." | 2.75 | Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. ( Au, JL; Bekaii-Saab, T; Chen, L; Grever, M; Guillaume Wientjes, M; Jensen, RR; Lam, ET; Li, X; Murgo, AJ; Otterson, GA; Shen, T; Villalona-Calero, MA; Wei, Y, 2010) |
| " STATEMENT OF SIGNIFICANCE: The doxorubicin-loaded glycol chitosan-suramin nanoparticle (GCS-SM/DOX) is novel in the following aspects: SM acts as not only a gelator for the first time in the preparation of the nanoparticle but also an active pharmaceutical agent in the dosage form." | 1.51 | Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles. ( Cheng, B; Gao, F; Maissy, E; Xu, P, 2019) |
| "Emodin is an anthraquinone derivative originally isolated from Chinese rhubarb, possesses anticancer properties." | 1.46 | Emodin Inhibits ATP-Induced Proliferation and Migration by Suppressing P2Y Receptors in Human Lung Adenocarcinoma Cells. ( Guan, R; Li, L; Shen, L; Song, N; Wang, X; Zhu, D, 2017) |
| "Suramin treatment before cisplatin administration reduced cisplatin-induced decreases in kidney function and injury." | 1.43 | Suramin protects from cisplatin-induced acute kidney injury. ( Arteel, GE; Beverly, LJ; Casson, L; Doll, MA; Dupre, TV; Jenson, AB; Kiefer, A; Megyesi, J; Saforo, D; Saurabh, K; Scherzer, MT; Schnellmann, RG; Shah, PP; Sharp, CN; Siow, D; Siskind, LJ, 2016) |
| " A dosing nomogram was developed by using population-based pharmacokinetic analysis of phase I results (15 patients, 85 treatment cycles), and evaluated in phase II patients (19 females, 28 males, 196 treatment cycles)." | 1.33 | Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development. ( Au, JL; Chen, D; Grever, M; Jensen, R; Murgo, AJ; Otterson, GA; Song, SH; Villalona-Calero, M; Wientjes, MG; Yeh, TK; Zhao, L, 2006) |
| "Suramin cytotoxicity was studied in a panel of human lung cancer cell lines by the MTT assay." | 1.29 | Effects of suramin on human lung cancer cell lines. ( Giaccone, G; Pinedo, HM; Rubio, GJ; van Ark-Otte, J; Virizuela, J, 1995) |
| "Suramin is a polyanionic agent which has been found to be an effective antineoplastic agent against various human tumors including adrenal, renal and prostatic cancer, and osteosarcoma." | 1.29 | Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer. ( Boyce, BF; Dunstan, C; Mundy, GR; Rhine, C; Williams, P; Yoneda, T, 1995) |
| " A dose-response experiment in the B16F10 melanoma model showed that inhibition of lung colony formation was still significant with 50 mg/kg pretreatment, whereas a borderline effect was observed at 10 mg/kg." | 1.29 | Inhibition of lung and liver tumor colonies in mice pretreated with suramin. ( Farao, M; Grandi, M; Mariani, M; Marsiglio, A; Sola, F, 1993) |
| "Suramin treatment resulted in a time- and dose-dependent decrease in [3H]thymidine incorporation, except in one adenocarcinoma cell line where DNA synthesis was highly stimulated." | 1.29 | In vitro effect of suramin on lung tumour cells. ( Lauber, B; Mórocz, IA; Schmitter, D; Stahel, RA, 1993) |
| "Treatment with suramin (Germanin) was begun in August 1987." | 1.28 | [Treatment of metastatic adrenal carcinoma with suramin]. ( Allolio, B; Arlt, W; Jaursch-Hancke, C; Metzler, U; Reincke, M; Winkelmann, W, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 16 (48.48) | 18.2507 |
| 2000's | 11 (33.33) | 29.6817 |
| 2010's | 5 (15.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acero, N | 1 |
| Braña, MF | 1 |
| Añorbe, L | 1 |
| Domínguez, G | 1 |
| Muñoz-Mingarro, D | 1 |
| Mitjans, F | 1 |
| Piulats, J | 1 |
| Wang, X | 1 |
| Li, L | 1 |
| Guan, R | 1 |
| Zhu, D | 1 |
| Song, N | 1 |
| Shen, L | 1 |
| Cheng, B | 1 |
| Gao, F | 1 |
| Maissy, E | 1 |
| Xu, P | 1 |
| Dupre, TV | 1 |
| Doll, MA | 1 |
| Shah, PP | 1 |
| Sharp, CN | 1 |
| Kiefer, A | 1 |
| Scherzer, MT | 1 |
| Saurabh, K | 1 |
| Saforo, D | 1 |
| Siow, D | 1 |
| Casson, L | 1 |
| Arteel, GE | 1 |
| Jenson, AB | 1 |
| Megyesi, J | 1 |
| Schnellmann, RG | 1 |
| Beverly, LJ | 1 |
| Siskind, LJ | 1 |
| Villalona-Calero, MA | 3 |
| Otterson, GA | 4 |
| Wientjes, MG | 5 |
| Weber, F | 1 |
| Bekaii-Saab, T | 2 |
| Young, D | 2 |
| Murgo, AJ | 4 |
| Jensen, R | 2 |
| Yeh, TK | 3 |
| Wei, Y | 2 |
| Zhang, Y | 1 |
| Eng, C | 1 |
| Grever, M | 4 |
| Au, JL | 7 |
| Lam, ET | 1 |
| Guillaume Wientjes, M | 1 |
| Chen, L | 1 |
| Shen, T | 1 |
| Li, X | 1 |
| Jensen, RR | 1 |
| Kanter, S | 1 |
| Fischer, B | 1 |
| DeHoff, C | 1 |
| Chen, D | 2 |
| Song, S | 3 |
| Lu, Z | 1 |
| Wientjes, TS | 1 |
| Zhang, P | 2 |
| He, JB | 2 |
| Ou, LW | 1 |
| Wang, XH | 1 |
| Song, SH | 1 |
| Zhao, L | 1 |
| Villalona-Calero, M | 1 |
| Guo, K | 1 |
| Li, J | 1 |
| Wang, H | 1 |
| Osato, M | 1 |
| Tang, JP | 1 |
| Quah, SY | 1 |
| Gan, BQ | 1 |
| Zeng, Q | 1 |
| Dua, P | 1 |
| Ingle, A | 1 |
| Gude, RP | 1 |
| Tatur, S | 1 |
| Groulx, N | 1 |
| Orlov, SN | 1 |
| Grygorczyk, R | 1 |
| Yi, GZ | 1 |
| Yang, K | 1 |
| Xiang, Z | 1 |
| Xie, MF | 1 |
| Gil, M | 1 |
| Skopińska-Rózewska, E | 1 |
| Radomska, D | 1 |
| Demkow, U | 1 |
| Skurzak, H | 1 |
| Rochowska, M | 1 |
| Beuth, J | 1 |
| Roszkowski, K | 1 |
| Rubio, GJ | 1 |
| Pinedo, HM | 1 |
| Virizuela, J | 1 |
| van Ark-Otte, J | 1 |
| Giaccone, G | 1 |
| Yoneda, T | 1 |
| Williams, P | 1 |
| Rhine, C | 1 |
| Boyce, BF | 1 |
| Dunstan, C | 1 |
| Mundy, GR | 1 |
| Lelièvre, S | 2 |
| Benchokroun, Y | 1 |
| Larsen, AK | 3 |
| Favoni, RE | 1 |
| Ravera, F | 1 |
| Pirani, P | 1 |
| Ardizzoni, A | 1 |
| Noonan, D | 1 |
| de Cupis, A | 1 |
| Bojanowski, K | 1 |
| Nishio, K | 1 |
| Fukuda, M | 1 |
| Saijo, N | 1 |
| Sola, F | 1 |
| Farao, M | 1 |
| Marsiglio, A | 1 |
| Mariani, M | 1 |
| Grandi, M | 1 |
| Fujiuchi, S | 1 |
| Tsuji, T | 1 |
| Ohsaki, Y | 1 |
| Kikuchi, K | 1 |
| Mórocz, IA | 1 |
| Lauber, B | 1 |
| Schmitter, D | 1 |
| Stahel, RA | 1 |
| Lokshin, A | 2 |
| Levitt, ML | 2 |
| Mirza, MR | 1 |
| Jakobsen, E | 1 |
| Pfeiffer, P | 1 |
| Lindebjerg-Clasen, B | 1 |
| Bergh, J | 1 |
| Rose, C | 1 |
| Kakeji, Y | 1 |
| Teicher, BA | 1 |
| Peng, X | 1 |
| Campbell, PG | 1 |
| Barsouk, A | 1 |
| Gan, Y | 1 |
| Walsh, C | 1 |
| Putnam, EA | 1 |
| Yen, N | 1 |
| Gallick, GE | 1 |
| Steck, PA | 1 |
| Fang, K | 1 |
| Akpakip, B | 1 |
| Gazdar, AF | 1 |
| Roth, JA | 1 |
| Baldus, M | 1 |
| Allolio, B | 2 |
| Brass, H | 1 |
| Jaursch-Hancke, C | 1 |
| Reincke, M | 1 |
| Arlt, W | 1 |
| Metzler, U | 1 |
| Winkelmann, W | 1 |
4 trials available for suramin and Lung Neoplasms
| Article | Year |
|---|---|
Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2008 |
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, | 2010 |
Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; D | 2003 |
Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans | 1997 |
29 other studies available for suramin and Lung Neoplasms
| Article | Year |
|---|---|
Synthesis and biological evaluation of novel indolocarbazoles with anti-angiogenic activity.
Topics: Angiogenesis Inhibitors; Animals; Capillaries; Cell Line, Tumor; Cell Proliferation; Collagen; Drug | 2012 |
Emodin Inhibits ATP-Induced Proliferation and Migration by Suppressing P2Y Receptors in Human Lung Adenocarcinoma Cells.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Adenosine Triphosphate; bcl-2-Associated X Prote | 2017 |
Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.
Topics: Animals; Cell Line, Tumor; Chitosan; Doxorubicin; Female; Human Umbilical Vein Endothelial Cells; Hu | 2019 |
Suramin protects from cisplatin-induced acute kidney injury.
Topics: Acute Kidney Injury; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Apoptosis; Cell Line, Tumor; C | 2016 |
Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bromodeo | 2005 |
[Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Drug Synergi | 2006 |
Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.
Topics: Algorithms; Antineoplastic Agents; Blood Proteins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clin | 2006 |
PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo.
Topics: Animals; Blood Vessels; Cell Movement; CHO Cells; Coculture Techniques; Colorectal Neoplasms; Cricet | 2006 |
Suramin augments the antitumor and antimetastatic activity of pentoxifylline in B16F10 melanoma.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Ca2+-dependent ATP release from A549 cells involves synergistic autocrine stimulation by coreleased uridine nucleotides.
Topics: Adenosine Triphosphate; Apyrase; Autocrine Communication; Caffeine; Calcium; Calcium Signaling; Calc | 2007 |
[Inhibitory effects of suramin on growth of transplanted lung adencarcinoma in mice and its mechanisms].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Immunohistochemist | 2008 |
Effect of purinergic receptor antagonists suramin and theobromine on tumor-induced angiogenesis in BALB/c mice.
Topics: Animals; Carcinoma; Injections, Subcutaneous; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neopl | 1993 |
Effects of suramin on human lung cancer cell lines.
Topics: Blotting, Northern; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance; Humans; Lung N | 1995 |
Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer.
Topics: Adenocarcinoma; Animals; Bone and Bones; Bone Resorption; Calcium; Carcinoma, Squamous Cell; Cell Di | 1995 |
Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Topics: Amsacrine; Animals; Camptothecin; Cell Nucleus; Cricetinae; Cricetulus; DNA Topoisomerases, Type I; | 1995 |
Suramin interferes with auto/paracrine insulin-like growth factor I-controlled proliferative loop on human lung cancer cell lines.
Topics: Adenocarcinoma; Binding, Competitive; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell | 1994 |
Effect of suramin on p34cdc2 kinase in vitro and in extracts from human H69 cells: evidence for a double mechanism of action.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Small Cell; CDC2 Protein Kinase; Cell Line; Cel | 1994 |
Development and characterization of suramin-resistant Chinese hamster fibrosarcoma cells: drug-dependent formation of multicellular spheroids and a greatly enhanced metastatic potential.
Topics: Animals; Cell Adhesion; Cell Count; Cell Division; Cricetinae; Cricetulus; Drug Resistance; Fibrosar | 1994 |
Inhibition of lung and liver tumor colonies in mice pretreated with suramin.
Topics: Animals; Dose-Response Relationship, Drug; Female; Liver Neoplasms; Lung Neoplasms; Lymphoma, Large | 1993 |
[The effect of suramin on human lung cancer cell line in vitro].
Topics: Cell Cycle; Cell Division; Epidermal Growth Factor; Humans; Lung Neoplasms; Suramin; Tumor Cells, Cu | 1994 |
In vitro effect of suramin on lung tumour cells.
Topics: DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Leucine; | 1993 |
Effect of suramin on squamous differentiation and apoptosis in three human non-small-cell lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Calcimycin; Carcinoma, Adenosquamous; Carcinoma, S | 1996 |
Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Anti | 1997 |
Mechanisms of growth stimulation by suramin in non-small-cell lung cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Cell Division; Dime | 1999 |
Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Culture Media, Conditioned; Doxorubic | 2000 |
Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Culture Media, Conditioned; Dose-Response R | 2001 |
Autocrine growth stimulation by transforming growth factor-alpha in human non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Humans; L | 1992 |
[Suramin--a new therapeutic principle in the treatment of metastatic adrenal gland cancer].
Topics: Adenoma; Adrenal Gland Neoplasms; Blood Coagulation Tests; Combined Modality Therapy; Drug Administr | 1990 |
[Treatment of metastatic adrenal carcinoma with suramin].
Topics: Adrenal Cortex Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modali | 1989 |